The Price of Substitute Technologies

Area of Science:

• Health economics
• Pharmaceutical policy
• Drug pricing regulation

Background:

• Most new drugs offer minimal innovation over existing alternatives.
• Health economic evaluations are crucial for setting acceptable prices for new health technologies.
• Threshold pricing strategies can guide the regulation of new therapeutic agents.

Purpose of the Study:

• To discuss a cost-effectiveness threshold (λ) for regulating the prices of substitute pharmaceutical technologies.
• To establish a framework for fair pricing of new drugs based on their incremental value.

Main Methods:

• Analysis of substitute technologies' marginal benefits and system efficiency.
• Postulation of opportunity cost threshold (κ) as maximum value.
• Identification of a threshold (β) that maximizes consumer surplus.
• Formulation of a listing criterion: treatment cost of substitute technology must be less than incumbent's cost plus the threshold-priced effectiveness difference.

Main Results:

• Pharmaceutical markets are unlikely to price drugs at production cost.
• The cost-effectiveness ratio of incumbent technology, below κ, is a viable estimate for λ.
• This estimate balances consumer benefit maximization with producer surplus for R&D incentives, falling between β and κ.

Conclusions:

• Pricing of substitute technologies should be capped by the cost-effectiveness ratio of the incumbent technology.
• This regulation ensures value-based pricing and supports continued innovation in the pharmaceutical sector.